- Anxiety
- Depression
- Alzheimer's Disease
- Weight Loss
- Heart Disease
- Cancer
- Asthma
Trial Phase
Trial Status
Paid Participation
Clear All
20 Schizophrenia Trials near Philadelphia, PA
Power is an online platform that helps thousands of Schizophrenia patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.
Learn More About PowerBehavioral Activation for Serious Mental Illness
Trial Details
Key Eligibility Criteria
52 Participants Needed
Taking Action Program for Serious Mental Illnesses
Trial Details
Key Eligibility Criteria
300 Participants Needed
Dopamine Receptor Agonist for Schizophrenia
Trial Details
Key Eligibility Criteria
120 Participants Needed
NBI-1117568 for Schizophrenia
Trial Details
Key Eligibility Criteria
284 Participants Needed
SEP-363856 for Schizophrenia
Trial Details
Key Eligibility Criteria
522 Participants Needed
Digital Therapeutics for Schizophrenia
Trial Details
Key Eligibility Criteria
432 Participants Needed
KarXT for Schizophrenia
Trial Details
Key Eligibility Criteria
280 Participants Needed
Xanomeline + Trospium for Schizophrenia
Trial Details
Key Eligibility Criteria
100 Participants Needed
ANAVEX3-71 for Schizophrenia
Trial Details
Key Eligibility Criteria
71 Participants Needed
LB-102 for Schizophrenia
Trial Details
Key Eligibility Criteria
350 Participants Needed
Emraclidine for Schizophrenia
Trial Details
Key Eligibility Criteria
850 Participants Needed
TV-44749 vs Oral Olanzapine for Schizophrenia
Trial Details
Key Eligibility Criteria
116 Participants Needed
KarXT for Schizophrenia
Trial Details
Key Eligibility Criteria
173 Participants Needed
KarXT for Schizophrenia
Trial Details
Key Eligibility Criteria
360 Participants Needed
SEP-363856 for Schizophrenia
Trial Details
Key Eligibility Criteria
67 Participants Needed
TV-44749 for Schizophrenia
Trial Details
Key Eligibility Criteria
675 Participants Needed
Long-term Safety of Iclepertin for Schizophrenia
Trial Details
Key Eligibility Criteria
1361 Participants Needed
Dexmedetomidine for Agitation in Schizophrenia and Bipolar Disorder
Trial Details
Key Eligibility Criteria
450 Participants Needed
Lumateperone for Schizophrenia
Trial Details
Key Eligibility Criteria
72 Participants Needed
ABBV-932 for Generalized Anxiety Disorder
Trial Details
Key Eligibility Criteria
72 Participants Needed
Why Other Patients Applied
"I’ve been diagnosed with Schizoaffective Disorder for over 5 years now and not found much relief in medication. One I’ve tried helped a bit but the side affects were overwhelming. Hoping I can gain some relief from this disorder and help advance research as well!"
"I would like to get a medication that has fewer side effects than the ones I've used. Many antipsychotics just make me numb or flat and I can't really think. Also I like the idea of helping in research to find better medications for schizephrenia."
"My psychosis has been manageable for the past few years since I found an antipsychotic that works okay but I still struggle with a lot of mind fog and memory issues. I haven't heard of a treatment for those symptoms until learning about new research so I'm hoping to join a trial to get access."
"I've tried lots of drugs and I still have symptoms. I'm not sure of my reality because the things I see and hear are still active. Maybe this will help one way or the other. I would be glad to help others in the future by testing a medication as well."
"I'm willing to try anything to help improve and manage my schizophrenia in any way. I do my best each day to keep the hallucinations at bay. I no longer hear voices but I don't want them to come back either. Most medicine I've tried hasn't help very much."
Know someone looking for new options?
Spread the word
Learn More About Power
We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.
Frequently Asked Questions
How much do Schizophrenia clinical trials in Philadelphia, PA pay?
Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range for Phase 2–4 trials (Phase 1 trials often pay substantially more). Further, most trials will cover the costs of a travel to-and-from the clinic.
How do Schizophrenia clinical trials in Philadelphia, PA work?
After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll be sorted into one of the treatment groups, and receive your study drug. For some trials, there is a chance you'll receive a placebo. Across Schizophrenia trials in Philadelphia, PA 30% of clinical trials have a placebo. Typically, you'll be required to check-in with the clinic every month or so. The average trial length in Philadelphia, PA for Schizophrenia is 12 months.
How do I participate in a study as a "healthy volunteer"?
Not all studies recruit healthy volunteers: usually, Phase 1 studies do. Participating as a healthy volunteer means you will go to a research facility in Philadelphia, PA several times over a few days or weeks to receive a dose of either the test treatment or a "placebo," which is a harmless substance that helps researchers compare results. You will have routine tests during these visits, and you'll be compensated for your time and travel, with the number of appointments and details varying by study.
What does the "phase" of a clinical trial mean?
The phase of a trial reveals what stage the drug is in to get approval for a specific condition. Phase 1 trials are the trials to collect safety data in humans. Phase 2 trials are those where the drug has some data showing safety in humans, but where further human data is needed on drug effectiveness. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. As a general rule, Phase 3 trials are more promising than Phase 2, and Phase 2 trials are more promising than phase 1.
Do I need to be insured to participate in a Schizophrenia medical study in Philadelphia, PA?
Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.
What are the newest Schizophrenia clinical trials in Philadelphia, PA?
Most recently, we added NBI-1117568 for Schizophrenia, Xanomeline + Trospium for Schizophrenia and SEP-363856 for Schizophrenia to the Power online platform.
Why is schizophrenia more common now?
Most studies show the yearly number of new schizophrenia cases hasn’t skyrocketed; it only feels more common because doctors now catch milder cases and people with the illness live longer, so more are counted at any one time. Modern lifestyle changes—growing up in crowded cities, high-potency cannabis use, migration stress, older parenthood, and ongoing poverty—do add modest risk for certain groups, nudging overall figures upward. Recognising these drivers guides prevention efforts like early screening, substance-use education, urban social support, and good prenatal care.
What is the best injection for schizophrenia?
There isn’t one “best” injection for everyone with schizophrenia. Doctors usually choose among long-acting injectables such as paliperidone (monthly to every 6 months), aripiprazole (monthly or every 2–3 months) or risperidone (every 2 weeks to monthly) based on which oral version has helped you before, how often you can come for shots, and which side-effects you’re most sensitive to. Your psychiatrist will review these factors—plus cost, other health conditions and personal preference—to decide which LAI is the safest and most effective fit for you.
Who is most likely to recover from schizophrenia?
Research shows the best odds of meaningful recovery occur in people who get treatment quickly after their first symptoms, keep taking medication and using psychological/rehab supports, avoid alcohol or drugs, and have steady family or community support; women and those whose illness starts later in their 20s also tend to fare somewhat better, but these fixed factors matter less than the modifiable ones above. In short, while anyone with schizophrenia can improve, the combination of early intervention, sticking with care, healthy lifestyle, and strong social ties makes the biggest difference in who recovers.
Is schizophrenia inherited from mother or father?
Schizophrenia risk is passed down through many genes that you receive from both parents, and large studies do not show a consistent advantage of either the mother’s or the father’s side. Compared with the 1 % lifetime risk in the general population, the chance rises to about 10 % if one parent has schizophrenia and up to 40 % if both do; factors such as pregnancy complications, cannabis use, severe stress, or very advanced paternal age can add to that risk. Families with a history of the illness may benefit from genetic counselling and early mental-health check-ups during adolescence so any warning signs can be managed promptly.
How is schizophrenia viewed in China?
China does not have a single view of schizophrenia: in big cities many people now regard it as a treatable brain disorder, but in rural areas it may still be linked to spirit possession or seen as a source of family “shame,” so relatives often hide the illness and shoulder most care. High stigma persists because unusual behaviour is felt to threaten the family’s “face,” yet government programs such as the nationwide 686 follow-up system and the 2013 Mental-Health Law are expanding hospital care, community visits, and public education. Overall, attitudes are gradually shifting toward acceptance, but progress is uneven and support for both patients and their families remains a work in progress.
Are there any clinical trials being done for schizophrenia?
Yes—dozens of studies are actively recruiting worldwide, ranging from novel medicines like KarXT (muscarinic M1/M4 agonist), ulotaront (TAAR1 agonist), and roluperidone (aimed at negative symptoms) to long-acting weekly risperidone implants (TV-46000) and app-based cognitive programs. You can see real-time listings, eligibility criteria, and locations by typing “schizophrenia” into ClinicalTrials.gov or the EU Clinical Trials Register and then reviewing the options with your psychiatrist to weigh potential benefits, risks, and travel demands.
What is the biggest problem of schizophrenia?
Schizophrenia isn’t defined by one “biggest problem”; clinicians group its effects into positive symptoms (hallucinations/delusions), disorganization, negative symptoms (loss of drive, social withdrawal) and cognitive deficits. Studies show that after acute psychosis is controlled, the lasting obstacles to working, studying and maintaining relationships are usually the negative and cognitive symptoms, so effective care pairs antipsychotic medication with therapies and skills training that rebuild motivation, thinking and daily-living abilities.
Who has the highest rate of schizophrenia?
Worldwide, the single highest recorded rates occur in young adult Black Caribbean or Black African men who are migrants (or children of migrants) living in large urban areas; their chance of developing schizophrenia can be 4- to 9-times higher than that of white native-born residents. In general, men have a modestly higher risk than women (about 1.4 : 1), but factors such as minority or migrant status and growing up in a high-density city raise risk far more than sex alone.
What's the latest schizophrenia can develop?
Most people who develop schizophrenia do so between their late teens and early 30s, but experts recognise “late-onset” cases appearing at 40-60 and a rarer “very-late-onset schizophrenia-like psychosis” beginning after 60. Because psychosis this late in life is uncommon and can mimic problems such as dementia, stroke, or severe depression, anyone with new hallucinations or delusions at these ages should be evaluated promptly by a mental-health professional and a physician to sort out the cause and start the right treatment.